In its motion for a new trial, Platform Science emphasized that much of the evidence presented by Omnitracs was “legally irrelevant and highly prejudicial.” It also challenged the jury instructions regarding “willful blindness”—the notion that the company purposefully avoided acknowledging its alleged infringement—arguing these instructions were improper.
Platform Science $19.3M Verdict : Focus on the ‘308 Patent
Platform Science’s motions specifically target the verdict related to the ‘308 patent and do not dispute the jury’s finding that the company did not infringe two other patents owned by Omnitracs: U.S. Patent Nos. 9,262,934 and 10,255,575.
Legal Representation
Omnitracs and XRS are represented by a team from Kirkland & Ellis LLP, while Platform Science is represented by attorneys from Fish & Richardson PC and King & Spalding LLP. Neither party has commented on the motions.
